Unveiling the Dynamics of the Omicron Variant: Prevalence, Risk Factors, and Vaccination Efficacy during the Third Wave of Covid-19 in Indonesia's Gowa Regency
DOI:
https://doi.org/10.6000/1929-6029.2023.12.14Keywords:
Seroprevalence, SARS-Cov-2, COVID-19, VaccinationAbstract
Introduction: In February-March 2022, the B.1.1.529 (Omicron) variant of SARS-CoV-2 became the cause of the third wave of COVID-19 in Indonesia. However, data on the prevalence of the effects of the third wave of the COVID-19 pandemic are still limited, especially in regencies/cities in Indonesia. Gowa Regency is one of the most affected areas by COVID-19 in South Sulawesi.
Objective: Ascertaining risk factors associated with infection and evaluating the effectiveness of vaccination programs in Gowa Regency.
Methods: In March 2022, venous blood specimens were taken from 859 randomly selected samples in Gowa Regency to determine the presence of antibodies to SARS-CoV-2 by examining chemiluminescent microparticle immunoassay (CMIA) specimens. Information on demographics, previous infection history, symptoms, comorbid diseases, and vacancy status was collected through interviews. Data analysis was conducted using descriptive, bivariate tests with chi-square and One-way ANOVA, and multivariate tests using logistic regression.
Results: The overall prevalence of anti-SARS-CoV-2-IgG was 98.7%. The results showed that the prevalence of SARS-CoV-2 antibodies was not significantly different in terms of sex (P=0.306), age group (P=0.190), education (P=0.749), and occupation (P=0.685), history of COVID-19 symptoms (P=0.108), history of confirmation of COVID-19 (P=0.352), and history of comorbid diseases (P=0.477). However, this study showed that the prevalence of SARS-CoV-2 antibodies differed significantly among the fully vaccinated and incomplete groups (P <0.001).
Conclusion: There was a significant difference between the antibody status of respondents who had been fully vaccinated (at least two doses) and respondents who had not completed the vaccination.
References
Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. The Lancet 2020; 395: 1015-1018. https://doi.org/10.1016/S0140-6736(20)30673-5 DOI: https://doi.org/10.1016/S0140-6736(20)30673-5
WHO. WHO Coronavirus (COVID-19) Dashboard, https://covid19.who.int (accessed 22 March 2023).
Aditama TY. Dua Tahun Pandemi COVID-19. ejki 2022; 10: 1-3. https://doi.org/10.23886/ejki.10.157.1-3 DOI: https://doi.org/10.23886/ejki.10.157.1-3
World health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, https://apps.who.int/iris/handle/10665/331656 (2020, accessed 22 March 2023).
Rachman BE, Rusli M, Miftahussurur M. The Hidden Vulnerability of COVID-19 Observed from Asymptomatic Cases in Indonesia. Systematics Reviews in Pharmacy 2020; 11: 703-713.
Stringhini S. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. The Lancet 2020; 396: 313-319. https://doi.org/10.1016/S0140-6736(20)31304-0 DOI: https://doi.org/10.1016/S0140-6736(20)31304-0
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396: 535-544. https://doi.org/10.1016/S0140-6736(20)31483-5 DOI: https://doi.org/10.1016/S0140-6736(20)32266-2
He Z. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. The Lancet 2021; 397: 1075-1084. https://doi.org/10.1016/S0140-6736(21)00238-5 DOI: https://doi.org/10.1016/S0140-6736(21)00238-5
Clarke KEN. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021-February 2022. Morbidity and Mortality Weekly Report 2022; 71: 606-608. https://doi.org/10.15585/mmwr.mm7117e3 DOI: https://doi.org/10.15585/mmwr.mm7117e3
Galanis P, Vraka I, Fragkou D, et al. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect 2021; 108: 120-134. https://doi.org/10.1016/j.jhin.2020.11.008 DOI: https://doi.org/10.1016/j.jhin.2020.11.008
Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun 2020; 11: 3500. https://doi.org/10.1038/s41467-020-17318-x DOI: https://doi.org/10.1038/s41467-020-17318-x
Sydney ER, Kishore P, Laniado I, et al. Antibody evidence of SARS-CoV-2 infection in healthcare workers in the Bronx. Infection Control & Hospital Epidemiology 2020; 41: 1348-1349. https://doi.org/10.1017/ice.2020.437 DOI: https://doi.org/10.1017/ice.2020.437
Anand S. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. The Lancet 2020; 396: 1335-1344. https://doi.org/10.1016/S0140-6736(20)32009-2 DOI: https://doi.org/10.1016/S0140-6736(20)32009-2
Lai C-C, Wang J-H, Hsueh P-R. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. International Journal of Infectious Diseases 2020; 101: 314-322. https://doi.org/10.1016/j.ijid.2020.10.011 DOI: https://doi.org/10.1016/j.ijid.2020.10.011
Slot E. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. Nature Communications; 11. Epub ahead of print 2020. https://doi.org/10.1038/s41467-020-19481-7 DOI: https://doi.org/10.1038/s41467-020-19481-7
Uyoga S. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science 2021; 371: 79-82. https://doi.org/10.1126/science.abe1916 DOI: https://doi.org/10.1126/science.abe1916
Herlinda O, Bella A, Kusnadi G, et al. Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia. PLoS One 2021; 16: e0261931. https://doi.org/10.1371/journal.pone.0261931 DOI: https://doi.org/10.1371/journal.pone.0261931
Megasari NLA, Utsumi T, Yamani LN, et al. Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. PLoS One 2021; 16: e0251234. https://doi.org/10.1371/journal.pone.0251234 DOI: https://doi.org/10.1371/journal.pone.0251234
Sawitri AAS, Yuliyatni PCD, Astuti PAS, et al. Seroprevalence of SARS-CoV-2 antibodies in Bali Province: Indonesia shows underdetection of COVID-19 cases by routine surveillance. PLOS Glob Public Health 2022; 2: e0000727. https://doi.org/10.1371/journal.pgph.0000727 DOI: https://doi.org/10.1371/journal.pgph.0000727
Hoang VT, Pham TD, Nguyen QT, et al. Seroprevalence of SARS-CoV-2 among high-density communities and hyper-endemicity of COVID-19 in Vietnam. Tropical Medicine & International Health 2022; 27: 515-521. https://doi.org/10.1111/tmi.13744 DOI: https://doi.org/10.1111/tmi.13744
Ndongo FA, Guichet E, Mimbé ED, et al. Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon. Emerg Infect Dis 2022; 28: 1233-1236. https://doi.org/10.3201/eid2806.212580 DOI: https://doi.org/10.3201/eid2806.212580
González F, Vielot NA, Sciaudone M, et al. Seroepidemiology of SARS-CoV-2 infections in an urban Nicaraguan population. medRxiv 2021; 2021.02.25.21252447. https://doi.org/10.1101/2021.02.25.21252447 DOI: https://doi.org/10.1101/2021.02.25.21252447
Mercado-Reyes MM, Daza M, Pacheco A, et al. Seroprevalence of SARS-CoV-2 Antibodies in Children and Adolescents: Results From a Population-Based Survey in 10 Colombian Cities. Glob Pediatr Health 2022; 9: 2333794X221085385. https://doi.org/10.1177/2333794X221085385 DOI: https://doi.org/10.1177/2333794X221085385
Byambasuren O, Dobler CC, Bell K, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLoS ONE 2021; 16: e0248946. https://doi.org/10.1371/journal.pone.0248946 DOI: https://doi.org/10.1371/journal.pone.0248946
van Gils MJ, van Willigen HDG, Wynberg E, et al. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Reports Medicine 2022; 3: 100486. https://doi.org/10.1016/j.xcrm.2021.100486 DOI: https://doi.org/10.1016/j.xcrm.2021.100486
Uprichard SL, O’Brien A, Evdokimova M, et al. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals. Viruses 2022; 14: 370. https://doi.org/10.3390/v14020370 DOI: https://doi.org/10.3390/v14020370
Elangovan D, Hussain SMS, Virudhunagar Muthuprakash S, et al. Impact of COVID-19 Vaccination on Seroprevalence of SARS-CoV-2 among the Health Care Workers in a Tertiary Care Centre, South India. Vaccines (Basel) 2022; 10: 1967. https://doi.org/10.3390/vaccines10111967 DOI: https://doi.org/10.3390/vaccines10111967
Uysal EB, Gümüş S, Bektöre B, et al. Evaluation of antibody response after COVID‐19 vaccination of healthcare workers. Journal of Medical Virology 2022; 94: 1060-1066. https://doi.org/10.1002/jmv.27420 DOI: https://doi.org/10.1002/jmv.27420
Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 2021; 21: 475-484. https://doi.org/10.1038/s41577-021-00578-z DOI: https://doi.org/10.1038/s41577-021-00578-z
Emanuel EJ, Osterholm M, Gounder CR. A National Strategy for the “New Normal” of Life With COVID. JAMA 2022; 327: 211. https://doi.org/10.1001/jama.2021.24282 DOI: https://doi.org/10.1001/jama.2021.24282
Anshory M, Wahono CS, Pratama MZ, et al. Factors Associated with Vaccine Breakthrough Incidence among Health Care Workers Vaccinated with Inactivated SARS-CoV2 Vaccine (CoronaVac). Journal of Research in Health Sciences; 22. Epub ahead of print 30 June 2022. https://doi.org/10.34172/jrhs.2022.86 DOI: https://doi.org/10.34172/jrhs.2022.86
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
